» Articles » PMID: 33481108

Sarcopenia Predicts Worse Postoperative Outcomes and Decreased Survival Rates in Patients with Colorectal Cancer: a Systematic Review and Meta-analysis

Overview
Date 2021 Jan 22
PMID 33481108
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Previous studies have shown an association of sarcopenia with adverse short- and long-term outcomes in multiple gastrointestinal cancer types. We aimed to investigate the prognostic value of sarcopenia on the postoperative outcomes and survival rates of patients with colorectal cancer (CRC).

Methods: A systematic literature search was performed using the PubMed, Embase, Cochrane, Google Scholar, and Scopus databases. We included studies that compared postoperative outcomes or survival rates in sarcopenic and non-sarcopenic patients with CRC.

Results: A total of 44 observational studies, comprising 18,891 patients, were included. The pooled prevalence of sarcopenia was 37% (n = 7009). The pooled analysis revealed an association between sarcopenia and higher risk of total postoperative complications (23 studies, OR = 1.84; 95% CI 1.35-2.49), postoperative severe complications (OR = 1.72; 95% CI 1.10-2.68), postoperative mortality (OR = 3.21; 95% CI 2.01-5.11), postoperative infections (OR = 1.40; 95% CI 1.12-1.76), postoperative cardiopulmonary complications (OR = 2.92; 95% CI 1.96-4.37), and prolonged length of stay (MD = 0.77; 95% CI 0.44-1.11) after colorectal cancer surgery. However, anastomotic leakage showed comparable occurrence between sarcopenic and non-sarcopenic patients (OR = 0.99; 95% CI 0.72 to 1.36). Regarding survival outcomes, sarcopenic patients had significantly shorter overall survival (25 studies, HR = 1.83; 95% CI = 1.57-2.14), disease-free survival (HR = 1.55; 95% CI = 1.29-1.88), and cancer-specific survival (HR = 1.77; 95% CI 1.40-2.23) as compared with non-sarcopenic patients.

Conclusion: Among patients with colorectal cancer, sarcopenia is a strong predictor of increased postoperative complications and worse survival outcomes.

Citing Articles

Impact of Preoperative CT-Measured Sarcopenia on Clinical, Pathological, and Oncological Outcomes After Elective Rectal Cancer Surgery.

Martin D, Billy M, Becce F, Maier D, Schneider M, Dromain C Diagnostics (Basel). 2025; 15(5).

PMID: 40075876 PMC: 11899399. DOI: 10.3390/diagnostics15050629.


A Scoping Review of the Implications and Applications of Body Composition Assessment in Locally Advanced and Locally Recurrent Rectal Cancer.

Mai D, Drami I, Pring E, Gould L, Rai J, Wallace A Cancers (Basel). 2025; 17(5).

PMID: 40075693 PMC: 11899338. DOI: 10.3390/cancers17050846.


Low skeletal muscle mass as a proxy marker of sarcopenia is a risk factor for major complications in older patients undergoing curative colon resections for colon cancer.

Tirnova I, Gasimova M, Akay H, Sariturk C, Guven Mert A, Yenidunya O Front Med (Lausanne). 2025; 11():1464978.

PMID: 39850105 PMC: 11754278. DOI: 10.3389/fmed.2024.1464978.


Evaluating the Impact of Multimodal Prehabilitation with High Protein Oral Nutritional Supplementation (HP ONS) with Beta-Hydroxy Beta-Methylbutyrate (HMB) on Sarcopenic Surgical Patients-Interim Analysis of the HEROS Study.

Koh F, Yik V, Chin S, Kok S, Lee H, Tong C Nutrients. 2025; 16(24.

PMID: 39770973 PMC: 11677323. DOI: 10.3390/nu16244351.


Sarcopenia as a Prognostic Factor and Multimodal Interventions in Breast Cancer.

Du L, Liu X, Zhu Q, Zhu K, Li P Int J Gen Med. 2025; 17:6605-6616.

PMID: 39764482 PMC: 11701243. DOI: 10.2147/IJGM.S497897.


References
1.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

2.
Okugawa Y, Toiyama Y, Hur K, Yamamoto A, Yin C, Ide S . Circulating miR-203 derived from metastatic tissues promotes myopenia in colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019; 10(3):536-548. PMC: 6596405. DOI: 10.1002/jcsm.12403. View

3.
Aleixo G, Shachar S, Nyrop K, Muss H, Malpica L, Williams G . Myosteatosis and prognosis in cancer: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019; 145:102839. DOI: 10.1016/j.critrevonc.2019.102839. View

4.
Simonsen C, Heer P, Bjerre E, Suetta C, Hojman P, Pedersen B . Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical Oncology: A Meta-analysis. Ann Surg. 2018; 268(1):58-69. DOI: 10.1097/SLA.0000000000002679. View

5.
Lee C, Kang J . Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2020; 11(5):1270-1282. PMC: 7567135. DOI: 10.1002/jcsm.12575. View